The Regulation of Coagulation in Major Orthopedic surgery reducing the Risk of DVT and PE (RECORD) clinical program of rivaroxaban consists of 4 phase III clinical trials comparing rivaroxaban with enoxaparin for the prevention of venous thromboembolism (VTE) in patients undergoing either total hip or total knee replacement surgery. Despite the comprehensive and extensive nature of this program, it had some logistic issues that included the dosing of the enoxaparin which was not only inconsistent with the recommendations but the dosages used were not optimal. The duration of treatment while consistent with rivaroxaban did vary with enoxaparin and was somewhat short. The bleeding definitions and safety evaluations were not consistent in accordance with the current recommendations. Moreover, the RECORD program has no power to show differences in major bleeding. The cardiovascular rebound phenomenon should have been adequately addressed and may require additional clinical validation to establish the safety of rivaroxaban. Although the US Food and Drug Administration (FDA) advisory committee has recommended approval of rivaroxaban, the reported analysis strongly suggests additional clinical validation on the claimed benefit/risk ratio of this monotherapeutic anticoagulant.
Introduction
Rivaroxaban (BAY 59-7939) is an oral anticoagulant that is a direct inhibitor of factor Xa (FXa). Inhibition of FXa produces antithrombotic effects by decreasing the amplified generation of thrombin by the prothrombinase complex, thus diminishing thrombinmediated activation of both coagulation and platelets, without affecting the activity of thrombin itself.
The Regulation of Coagulation in Major Orthopedic surgery reducing the Risk of DVT and PE (RECORD) 1-4 studies were all phase III multinational, multicenter, randomized, double-blind studies on elective total hip replacement (THR) or total knee replacement (TKR) patients. [1] [2] [3] [4] All patients received either 10 mg of rivaroxaban once daily (od) orally, beginning 6 to 8 hours after wound closure and every 24 hours thereafter, or enoxaparin subcutaneously 40 mg od, the first injection given 12 hours preoperatively, the second injection given 6 to 8 hours after wound closure and thereafter every 24 hours in RECORD 1-3, while in RECORD 4, the enoxaparin dose was 30 mg twice a day (bid) and the first injection started 12 hours after surgery as this is the recommended US practice. Thereafter, study drugs were administered every 24 hours and in addition all patients received a placebo tablet or injection accordingly. The duration of the drug administration was different in each study (please see below).
The primary efficacy outcome was the composite of deep-vein thrombosis (DVT), either symptomatic or detected by bilateral venography if the patient was asymptomatic, nonfatal pulmonary embolism (PE), or death from any cause at 36 days (range, 30-42). Venography was mandatory and was scheduled after the last dose of the drug was administered. Followup was also arranged approximately 35 days after the last dose of the study drug. The main secondary efficacy outcome was the occurrence of major venous thromboembolism (VTE; proximal DVT, nonfatal PE, or death from VTE). The primary safety outcome was major bleeding excluding surgical sites. Analyses were done in the modified intention-to-treat population, which consisted of all patients who had received at least 1 dose of study medication, had undergone planned surgery, and had adequate assessment of VTE.
The duration of prophylaxis, the number of patients included together with the VTE endpoints and hemorrhagic complications appear below for each study. They are also depicted in Table 1 .
In the RECORD 1 study, 4541 THR patients were randomized to receive either the tablet or the injection for 35 days. A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P < .001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P < .001). Symptomatic venous thromboembolism occurred in 6 of 2193 patients (0.3%) in the rivaroxaban group and in 11 of 2206 patients (0.5%) in the enoxaparin group (absolute risk reduction, 0.2%; 95% CI, -0.6 to 0.1; P ¼ .22). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P ¼ .18).
In the RECORD 2 study, 2509 THR patients were randomized to receive the tablet for 35 days and the injection for 10 to 14 days. The modified intention-to-treat population for the analysis of the primary efficacy outcome consisted of 864 patients in the rivaroxaban group and 869 in the enoxaparin group. The primary outcome occurred in 17 (2.0%) patients in the rivaroxaban group, compared with 81 (9.3%) in the enoxaparin group (absolute risk reduction 7.3%, 95% CI 5.2-9.4; P < .0001). The incidence of any on-treatment bleeding was 81 (6.6%) events in 1228 patients in the rivaroxaban safety population vs 68 (5.5%) of 1229 patients in the enoxaparin safety population (P ¼ .25).
In the RECORD 3 study 2531 TKR patients were randomized to receive either the tablet or the injection for 12 days. The primary efficacy outcome occurred in 79 of 824 patients (9.6%) who received rivaroxaban and in 166 of 878 (18.9%) who received enoxaparin (absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P < .001). Major VTE occurred in 9 of 908 patients (1.0%) given rivaroxaban and 24 of 925 (2.6%) given enoxaparin (absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P ¼ .01). Symptomatic events occurred less frequently with rivaroxaban than with enoxaparin (P ¼ .005). Major bleeding occurred in 0.6% of patients in the rivaroxaban group and 0.5% of patients in the enoxaparin group. The incidence of drugrelated adverse events, mainly gastrointestinal, was 12.0% in the rivaroxaban group and 13.0% in the enoxaparin group.
In the RECORD 4 study, 3148 TKR patients were randomized to receive either the tablet or 30 mg bid enoxaparin (initiated 12 to 24 hours postoperatively) for 12 days when they had their venography. Rivaroxaban significantly reduced the incidence of the primary efficacy outcome compared with enoxaparin (6.9% vs 10.1%, respectively, P ¼ .012; relative risk reduction 31%). The observed incidences of major VTE and symptomatic VTE in those receiving rivaroxaban or enoxaparin were 1.2% vs 2.0% (P ¼ .124) and 0.7% vs 1.2% (P ¼ .187), respectively. The rates of major bleeding were 0.7% vs 0.3% (P ¼ .110), respectively. Major and clinically relevant nonmajor bleeding (CRNMB) was 3.0 in the rivaroxaban vs 2.3% in the enoxaparin group (P ¼ .179).
At a meeting of the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee on March 19, 2009, members of the committee recommended approval of rivaroxaban by a vote of 15 to 2 for prophylaxis of DVT and PE in patients undergoing hip and knee replacement surgery. 5 The RECORD 1-4 clinical evaluation program represents the supportive Phase III clinical data on the safety and efficacy of rivaroxaban in these indications. The following represents an independent and objective assessment of this program and points to some critical issues relative to the safety of this drug in the proposed indication.
Issues With the Use of Enoxaparin as Comparator in Rivaroxaban Phase III RECORD Trials
Within the RECORD program, there are several issues that can affect the evaluation of the benefit/ risk provided by rivaroxaban in comparison to enoxaparin. These include issues related to the dosing and treatment duration with enoxaparin as well as the way bleeding risks were reported. Complicated wound site hemorrhages and wound infection are important and such data should be reported in detail. The issues addressed in this review are from the US standpoint.
Two of the 4 Phase III RECORD studies were not appropriate for the US clinical use of the comparator drug, enoxaparin. RECORD 3 trial used a regimen not approved for enoxaparin in United States for TKR, whereas RECORD 2 used a preoperative dose which is not commonly used in the United States and compared 2 unequal arms in terms of treatment duration. Data from these trials are likely to have resulted in underestimation of enoxaparin's benefit relative to the risk of major along with clinically-relevant nonmajor bleeding (MB þ CRNMB) compared with rivaroxaban.
Dosing
In patients undergoing TKR surgery, the recommended dose of enoxaparin is 30 mg every 12 hours according to US prescribing information. 8 In the RECORD 3 trial, TKR surgery, the dose of enoxaparin used was 40 mg once daily for 10 to 14 days. This dose is not approved in the US enoxaparin label for thromboprophylaxis in TKR surgery. In contrast, in the RECORD 4 trial, TKR surgery, the dose of enoxaparin was 30 mg bid for 10 to14 days and therefore this study should be considered as the study providing appropriate comparative data for VTE prevention in TKR surgery in context of US labeling and clinical practice.
In RECORD 3, the absolute risk difference for the primary end point (any DVT, nonfatal PE, and all cause mortality) between enoxaparin and rivaroxaban was 9.2%. In RECORD 4, using the US-approved 30 mg bid dosing of enoxaparin, the absolute risk difference was much lower at 3.2% although both studies were designed for the same indication. Similarly, the significant difference in the incidence of symptomatic VTE observed in RECORD 3 (enoxaparin 2% vs rivaroxaban 0.7% P ¼ .005) was not demonstrated in the RECORD 4 trial where the difference in the incidence of symptomatic VTE was not statistically significant between treatments (1.2% for enoxaparin vs 0.7% for rivaroxaban; P ¼ .187).
Duration of Therapy
RECORD 2 was similar in study design, inclusion/ exclusion criteria, and endpoints to RECORD 1, except that enoxaparin 40 mg od (first dose given preoperatively) was given for a shorter duration (12 + 2 days) of time in comparison to rivaroxaban 10 mg od (35 + 4 days). Comparative efficacy claims to enoxaparin may not be drawn from this study, due to those differences in the treatment duration. White and Henderson in their review state that TKR is associated with a very high incidence of asymptomatic calf vein thrombosis, with almost all symptomatic VTE events diagnosed in the first 21 days after surgery. 6 THR is associated with a higher incidence of asymptomatic proximal thrombi and a modestly higher incidence of symptomatic VTE events, many diagnosed up to 6 or 8 weeks after hospital discharge. In RECORD 2, the difference in the exposure to enoxaparin was most likely responsible for a two and a half-fold increase in the incidence of the primary endpoint in the enoxaparin arm (9.3%) relative to RECORD 1 (3.7%) despite both studies having enrolled patients for the same indication. Furthermore, the rate of the symptomatic disease in RECORD 2 in the short-term enoxaparin arm was double that of long-term enoxaparin in RECORD 1 (1.2 % vs 0.5 %).
Similarly in RECORD 2, there were 4 more deaths in the enoxaparin group than in the rivaroxaban group, although there were no differences in death in RECORD 1 and RECORD 4 studies where US approved dosages were used. RECORD 2 could only be interpreted as supportive data on safety and efficacy of extended thromboprophylaxis, and not as a comparison of 2 different agents due to unequal treatment exposure. RECORD 2 data should not be pooled in metaanalyis along with other RECORD trials, as this may lead to misinterpretation of the risk / benefit of rivaroxaban versus enoxaparin.
Bleeding Definitions and Safety Evaluation
In the pooled analysis of the 4 RECORD trials reported at ASH 2008, 7 the incidence of major bleeding plus clinically relevant nonmajor bleeding (MB þ CRNMB) was significantly higher in patients treated with rivaroxaban when compared with those treated with enoxaparin (3.19% vs 2.55%; P ¼ .039). Additionally, in this analysis surgical bleeding was not included. Moreover, the definition of bleeding events differed from the EMEA and ISTH definitions. The RECORD 1-4 data should be reanalyzed to validate the safety claims by including surgical site bleeding. The incidence of major bleeding and clinically relevant nonmajor bleeding (MB þ CRNMB) represents a relative risk increase of 25% for rivaroxaban (95% CI 1.02-1.54) when compared with enoxaparin (absolute increase in risk of 0.64% for rivaroxaban over and above the risk with enoxaparin). Based on this data, the number-needed-to-harm (NNH) would be 156 for rivaroxaban, in which for every 156 patients treated with rivaroxaban (instead of enoxaparin) 1 additional major or clinically relevant nonmajor bleeding event would occur. The combined incidence of major bleeding plus surgical site bleeding was also lower in enoxaparin-treated patients 1.37% vs 1.80% for a RRI ¼ 1.31 (95% CI 0.99-1.73) that did not reach statistical significance (P ¼ .063). The RECORD clinical program was not powered to show difference in major bleeding, therefore statistical significance cannot be determined by conventional P < .05. Food and Drug Administration assessment has concluded that rivaroxaban group had excess bleeding for each bleeding definition.
Cardiovascular Rebound Phenomena in RECORD 1-4 Clinical Trial Program
Although the pooled data (both for THR and TKR) from the RECORD 1-4 studies failed to show a significant difference between rivaroxaban and enoxaparin arms, in terms of cardiovascular events following treatment discontinuation, it was suggestive of a higher prevalence of Acute Coronary Syndromes (ACS) rates in the RECORD 1, 2, and 4 trials. In the RECORD 3 trial, a higher prevalence of ACS in enoxaparin arm may have been due to dosing of enoxaparin at 40 mg od (10-14 days), which is not an approved dosage in the United States.
In the THR studies RECORD 1 and 2, rivaroxaban treatment was used for 35 days whereas in the TKR studies RECORD 3 and 4 the treatment duration of enoxaparin was only 10 to 14 days. When THR and TKR studies are pooled separately, ACS rebound effect becomes statistically significant with a higher prevalence of cardiovascular events in the rivaroxaban arm in contrast to enoxaparin.
Food and Drug Administration briefing document identified ''an isolated signal for potentially increased risk of cardiovascular events following rivaroxaban therapy. During this 'off treatment' period, the overall rate of cardiovascular events (myocardial infarction, ischemic stroke, cardiovascular, or unexplained death) was similar between the 2 study groups. However, ischemic stroke was reported in 5 rivaroxaban group patients and 1 enoxaparin group patient. Additionally, most cardiovascular events in the rivaroxaban group occurred shortly following the drug's discontinuation, whereas the events in the enoxaparin group were not concentrated in this period.''
The rebound cardiovascular (ACS) events reported with the use of rivaroxaban may be due to its monotherapeutic nature, targeting only FXa and relatively shorter duration of action after a single oral dose. Rebound phenomena have been previously reported with the use of synthetic thrombin inhibitors. In contrast, enoxaparin and other lowmolecular-weight heparins produced sustained antithrombotic effects which have been reported.
Other issues
Another issue is there is no antidote for rivaroxaban and no monitoring assay is available. 9 Regarding hepatotoxicity, the effect of an interaction of rivaroxaban with Cyp3A4 remains unclear and may be important in individuals using other drugs (antihypertensive and other effects) and in individuals with unrecognized hepatic disease.
Summary
The RECORD program presented to the FDA contains a single relevant study in THR (RECORD 1) and a single relevant study in TKR (RECORD 4) that were conducted with US approved doses and length of therapy of enoxaparin. Although RECORD 2 provides additional data on THR, the unbalanced design of the trial makes it inappropriate to use for comparative safety and efficacy of rivaroxaban versus enoxaparin. The relevant benefit/risk evaluation of these agents in US clinical practice should be considered using RECORD 1 and RECORD 4 trials data only. Further analysis of the benefit/risk of treatments in RECORD 1 and 4, comparing the absolute risk reduction in symptomatic VTE to absolute risk increase in MB þ CRNMB, indicates that the increase in bleeding risk with rivaroxaban exceeded the reduction in risk of symptomatic VTE compared to enoxaparin (RECORD The conclusions based on the pooled results from all 4 RECORD trials may provide a biased benefit/ risk representation of the results. This is because in RECORD 2 and 3 trials, which compared inappropriate regimens, the difference in efficacy is more marked in favor of rivaroxaban, especially in symptomatic disease (symptomatic VTE plus death). In the pooled data (from all four RECORD trials) presented at ASH 08, rates of MB þ CRNMB were significantly higher with rivaroxaban when compared with enoxaparin (3.19% vs 2.55%; P ¼ .039, RRI 1.25, 95% CI 1.02-1.54). There was also a clear and consistent trend in all 4 trials for increased major bleeding, and clinically relevant nonmajor bleeding, including surgical site, with rivaroxaban (1.37% vs 1.80%, RRI ¼ 1.31, 95% CI 0.99-1.73). This difference may not have reached statistical significance due to lack of power of trials to detect differences in major bleeding (P ¼ .063). The RECORD 1, 2, and 4 data is also suggestive that rivaroxaban use may be associated with a higher risk of ischemic and cardiovascular events upon discontinuation of the treatment cycle. Additional data from the ongoing rivaroxaban trials (AF and VTE treatment) will be crucial to further evaluate any relationship between cardiovascular events and the use of rivaroxaban.
Based on the above considerations, apart from the advantage of ease of oral administration, the use of rivaroxaban in the proposed indications for the prophylaxis of DVT in TKR and THR does not appear to offer sufficient benefits over the comparator drug used in the RECORD program. Furthermore, the increased risk of bleeding, potential for rebound cardiovascular events upon completion of the dosage cycle, and different population responses require additional clinical trials to validate the safety claims for rivaroxaban.
Note Added to Proof
The Cardiovascular and Renal Drugs Advisory Committee of the FDA conducted a public hearing on March 19, 2009, at Washington DC, under the chairmanship of Dr Michael Lincoff to discuss the safety and efficacy of rivaroxaban for prophylaxis in patients undergoing hip or knee replacement surgery. 5 The sponsors presented their data in support of their product. Major discussions focused on the 4 RECORD studies, in which the safety and efficacy of rivaroxaban was compared to that of enoxaparin an FDA-approved drug. Food and Drug Administration staff did a thorough review of the data submitted by the sponsors and in general agreed with the findings expressed in this editorial. Food and Drug Administration expressed their concern in the following areas: increased risk of bleeding, especially when used concomitant with other antiplatelet drugs, increased cerebrovascular events immediately following discontinuation of the drug, and possible hepatotoxicity. They also presented data on the statistical analysis done by using 2 different methods, which did not confirm the sponsors findings, that rivaroxaban was superior to enoxaparin in efficacy and safety. In view of the fact that FDA expressed major concern in terms of safety of this oral anticoagulant drug, it is wise to suggest additional studies, so that the safety issues are addressed thoroughly. Furthermore, it is also wise to recommend studies with a lower dose of the drug, to evaluate the relative safety and efficacy of this drug during hip and knee replacement surgery. One reason the bleeding rates may be higher with the 40 mg enoxaparin dose is the early administration of the postoperative dose of enoxaparin at 6 to 8 hours.
Although the meeting was considered an open hearing and time was allocated for public comments, the chair did not allow any statements from the public with exception of one prearranged discussion by a patient on behalf of the advocacy group. Several individuals expressed concern on the autocratic behavior of the chair of the advisory committee. The outcome could have been different if some of the individuals who wanted to make statements regarding the safety issues of rivaroxaban were given the opportunity to do so. It is reassuring that the advisory committee vote is not binding to the FDA and the agency will take into account all points of view prior to accepting the recommendations of the advisory committee.
